Subtype
Liver Carcinoma
CI-CAN-00001073Explore in graph →
783 active trials14 approved drugs17 evidence items
- NCIt
- C7927
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001073Explore in graph →
Clinical trials
3,370 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (387)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02143401 | Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 | 29 | National Cancer Institute (NCI)NIH | 1 | Nov 22, 2024 | clinicaltrials |
| NCT06290739 | A Machine-learning Model to Predict Lymph Node Metastasis of Intrahepatic Cholangiocarcinoma | completed | — | 483 | West China HospitalOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT00059267 | Prevention of Recurrent Hepatitis B After Liver Transplantation | completed | — | 317 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Nov 15, 2024 | clinicaltrials |
| NCT03268499 | Emulsion Versus Suspension in Chemoembolization for Hepatocellular Carcinoma | completed | N/A | 80 | Chinese University of Hong KongOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT03606590 | Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA) | completed | Phase 2 | 25 | NovoCure Ltd.INDUSTRY | 6 | Nov 14, 2024 | clinicaltrials |
| NCT04313868 | GEN2 Directed Cancer Immunotherapy Trial(GEN2) | completed | Phase 1 | 61 | GenVivo, Inc.INDUSTRY | 1 | Nov 6, 2024 | clinicaltrials |
| NCT05003700 | Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma | completed | Phase 2 | 39 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT04954794 | TACE Combined with Sintilimab Plus Bevacizumab Biosimilar in Patients with Advanced Hepatocellular Carcinoma (TASK-02) | completed | Phase 2 | 29 | Fudan UniversityOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT06663904 | Different Abbreviated MRI for Hepatocellular Carcinoma Diagnosis(AMRI; LIRADS) | completed | — | 938 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT03419897 | Study of BGB-A317 in Participants With Previously Treated Unresectable HCC | completed | Phase 2 | 249 | BeiGeneINDUSTRY | 8 | Oct 26, 2024 | clinicaltrials |
| NCT02511522 | Study of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases | completed | N/A | 66 | Canadian Cancer Trials GroupNETWORK | 1 | Oct 23, 2024 | clinicaltrials |
| NCT02325739 | FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression | completed | Phase 1 / Phase 2 | 172 | Novartis PharmaceuticalsINDUSTRY | 11 | Oct 21, 2024 | clinicaltrials |
| NCT06637059 | Artificially Intelligent Model for Accurate Detection of HCC | completed | — | 1,092 | Zhejiang UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT04011033 | Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC | completed | Phase 2 | 60 | Beijing YouAn HospitalOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT06629857 | A Cross Sectional Study Evaluating the Mean Levels of Alpha Fetoprotein in Patients of Hepatocellular Carcinoma and Its Correlates in Pakistan | completed | — | 94 | Darul Sehat HospitalOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT03253289 | Meclizine for Hepatocellular Carcinoma(OPTIM) | completed | Phase 1 | 13 | Tannaz ArmaghnayOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT06621485 | Calculator Predicts Early Mortality Post Hepatocellular Carcinoma Resection | completed | — | 4,966 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT05221398 | Adjuvant Immune Checkpoint Inhibitors in Postoperative Hepatocellular Carcinoma | completed | — | 517 | Guangxi Medical UniversityOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT03175679 | Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC | completed | Phase 1 | 10 | Beijing YouAn HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04310540 | PSMA PET/MRI or PSMA PET/CT for Evaluation of Liver Cancer | completed | Early Phase 1 | 42 | Mayo ClinicOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04401813 | Efficacy and Safety of IBI310 Combined with Sintilimab in Patients with Advanced Hepatocellular Carcinoma | completed | Phase 1 | 97 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02702414 | Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224) | completed | Phase 2 | 156 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 4, 2024 | clinicaltrials |
| NCT03299946 | Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 1 | 15 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT04170556 | Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING)(GOING) | completed | Phase 1 / Phase 2 | 69 | Fundacion Clinic per a la Recerca BiomédicaOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT01906216 | Sorafenib Chemoembolization Evaluation Controlled Trial(SELECT) | completed | Phase 3 | 199 | Air Force Military Medical University, ChinaOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT01752933 | SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 52 | Astex Pharmaceuticals, Inc.INDUSTRY | 3 | Aug 27, 2024 | clinicaltrials |
| NCT02112656 | Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)(OPTIMA) | completed | Phase 3 | 554 | ImunonINDUSTRY | 14 | Aug 20, 2024 | clinicaltrials |
| NCT02595866 | Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer | completed | Phase 1 | 58 | National Cancer Institute (NCI)NIH | 1 | Aug 9, 2024 | clinicaltrials |
| NCT02509507 | Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611(MASTERKEY-318) | completed | Phase 1 / Phase 2 | 127 | AmgenINDUSTRY | 9 | Aug 6, 2024 | clinicaltrials |
| NCT04166240 | Measuring and Improving the Safety of Test Result Follow-Up | completed | N/A | 46 | VA Office of Research and DevelopmentFED | 1 | Aug 6, 2024 | clinicaltrials |
| NCT03586050 | Study to Evaluate the Safety and Effectiveness of Microwave Ablation in Patients With Hepatocellular Carcinoma in Korea | completed | N/A | 33 | Ethicon, Inc.INDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT02856126 | HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC | completed | Phase 3 | 214 | Sun Yat-sen UniversityOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT04763408 | A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma(STELLAR) | completed | — | 335 | Eisai Inc.INDUSTRY | 10 | Jul 18, 2024 | clinicaltrials |
| NCT06505291 | Long-term Management of Patients With Ruptured HCC | completed | — | 112 | University Hospital, CaenOTHER | 0 | Jul 17, 2024 | clinicaltrials |
| NCT06496113 | Robotic Versus Laparoscopic Liver Resection for Hepatocellular Carcinoma | completed | — | 196 | Ente Ospedaliero Cantonale, BellinzonaOTHER | 0 | Jul 11, 2024 | clinicaltrials |
| NCT03510871 | Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 43 | National Health Research Institutes, TaiwanOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT03483922 | HCC Screening Using DNA Methylation Changes in ctDNA | completed | — | 403 | HKGepitherapeuticsINDUSTRY | 1 | Jul 5, 2024 | clinicaltrials |
| NCT03752398 | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)(DUET-3) | completed | Phase 1 | 198 | Xencor, Inc.INDUSTRY | 1 | Jul 5, 2024 | clinicaltrials |
| NCT04518852 | TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC | completed | Phase 2 | 27 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05690451 | Non-contrast Abbreviated MRI for Secondary Surveillance of HCC | completed | — | 210 | Seoul National University HospitalOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT03418922 | A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma | completed | Phase 1 | 30 | Eisai Co., Ltd.INDUSTRY | 1 | Jun 20, 2024 | clinicaltrials |
| NCT04047173 | RFA Versus SBRT for Recurrent Small HCC | completed | Phase 3 | 166 | Sun Yat-sen UniversityOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT06232759 | TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular Carcinoma | completed | Phase 2 | 56 | Guangxi Medical UniversityOTHER | 1 | Jun 10, 2024 | clinicaltrials |
| NCT00857805 | Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma | completed | N/A | 76 | Loma Linda UniversityOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT06437457 | Comparison of Gd-EOB-DTPA-enhanced MRI and Contrast-enhanced Ultrasound for Measuring Tumor Size of Solitary Hepatocellular Carcinoma ≤ 5cm:A Retrospective Study | completed | — | 194 | Anhui Medical UniversityOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT04172571 | A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 31 | AkesoINDUSTRY | 1 | May 30, 2024 | clinicaltrials |
| NCT06435013 | Lenvatinib vs Bevacizumab Plus ICIs and HAIC in Unresectable HCC | completed | — | 208 | Sun Yat-sen UniversityOTHER | 1 | May 30, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Nov 22, 2024source: clinicaltrials